Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.37 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091756 | 0.87 | CSNK1D (0.47) | CSNK1DMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3102248 | 0.85 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3108073 | 0.81 | GRM5 (0.43) | CSNK1DTRPC3TRPC7KCNK3GRIN2B | |
| SCHEMBL3090683 | 0.76 | THRB (0.41) | CSNK1DTHRBMAPK14GSK3BTGFBR1 | |
| SCHEMBL13254961 | 0.70 | MAPK14 (0.45) | CSNK1DMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3110918 | 0.70 | THRB (0.54) | CSNK1DTHRBMAPK14TGFBR1 | |
| SCHEMBL3105536 | 0.69 | CSNK1D (0.53) | CSNK1DMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL19998108 | 0.67 | THRB (0.45) | CSNK1DTHRBKCNK3TGFBR1 | |
| SCHEMBL3099814 | 0.67 | CSNK1D (0.38) | CSNK1DTHRBMAPK14MAPK13MAPK12 | |
| SCHEMBL30796964 | 0.67 | GRM5 (0.53) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217600-B1 | FUNGICIDAL BICYCLIC PYRAZOLES | DU PONT (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8288375-B2 | Fungicidal bicyclic pyrazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100273775-A1 | FUNGICIDAL BICYCLIC PYRAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273775-A1 | FUNGICIDAL BICYCLIC PYRAZOLES | CYP1B1, CBR1, CYP1A1 | CSNK1D 1670/4885TRPC3 4229/4885TRPC7 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.